[go: up one dir, main page]

WO2005079419A3 - Methods of treating immunopathological disorders - Google Patents

Methods of treating immunopathological disorders Download PDF

Info

Publication number
WO2005079419A3
WO2005079419A3 PCT/US2005/004895 US2005004895W WO2005079419A3 WO 2005079419 A3 WO2005079419 A3 WO 2005079419A3 US 2005004895 W US2005004895 W US 2005004895W WO 2005079419 A3 WO2005079419 A3 WO 2005079419A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
methods
component
disorders
tlr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2005/004895
Other languages
French (fr)
Other versions
WO2005079419A2 (en
Inventor
Eyal Raz
Vanessa Doreen Redecke
Anthony A Horner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of WO2005079419A2 publication Critical patent/WO2005079419A2/en
Publication of WO2005079419A3 publication Critical patent/WO2005079419A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention provides methods of treating immunopathological disorders having a Th1 component, e.g., autoimmune disorders and allograft rejection, and/or an M1 macrophage component, e.g., an M1-mediated inflammatory disorder. The methods generally involve administering to an individual in need thereof an effective amount of a toll-like receptor-2 (TLR2) agonist. The present invention provides combination therapies for treating an immunopathology having a Th1 and/or an M1 macrophage component, generally involving administering a TLR2 agonist and at least one additional therapeutic agent.
PCT/US2005/004895 2004-02-17 2005-02-16 Methods of treating immunopathological disorders Ceased WO2005079419A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54535304P 2004-02-17 2004-02-17
US60/545,353 2004-02-17

Publications (2)

Publication Number Publication Date
WO2005079419A2 WO2005079419A2 (en) 2005-09-01
WO2005079419A3 true WO2005079419A3 (en) 2006-07-06

Family

ID=34886139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/004895 Ceased WO2005079419A2 (en) 2004-02-17 2005-02-16 Methods of treating immunopathological disorders

Country Status (1)

Country Link
WO (1) WO2005079419A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0315810A (en) 2002-10-29 2005-09-13 Coley Pharmaceutical Group Ltd Use of cpg oligonucleotides in the treatment of hepatitis c virus infection
AU2003300919A1 (en) 2002-12-11 2004-06-30 Coley Pharmaceutical Gmbh 5' cpg nucleic acids and methods of use
US20090099191A1 (en) * 2006-02-02 2009-04-16 Gudkov Andrei V Inhibition of nf-kb
AU2008267151B2 (en) * 2007-06-28 2014-02-20 Neuramedy Co., Ltd. Composition and method for treatment of autoimmune disease
JP2010532334A (en) 2007-07-05 2010-10-07 オプソナ セラピューティクス リミテッド Compounds and methods for treating kidney disease
US8507507B2 (en) 2009-10-22 2013-08-13 Gilead Sciences, Inc. Modulators of toll-like receptors
EP3669892B1 (en) 2010-09-22 2024-05-08 ENA Respiratory Pty Ltd Composition for use in a immunostimulatory method
ES2979287T3 (en) * 2017-03-31 2024-09-25 Ena Respiratory Pty Ltd Respiratory infection treatment
WO2019119069A1 (en) * 2017-12-21 2019-06-27 Ena Therapeutics Pty Ltd Administration of a tlr2 agonist for the treatment or prevention of a respiratory condition associated with an infectious agent
KR102747437B1 (en) 2017-12-21 2024-12-26 악셀리아 온콜로지 피티와이 리미티드 Optimized compound
CN114174260B (en) 2019-06-26 2025-09-05 艾娜呼吸私人有限公司 New molecules

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
US6376528B1 (en) * 1996-02-13 2002-04-23 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849285A (en) * 1994-04-13 1998-12-15 Research Corporation Technologies, Inc. Autoimmune disease treatment with sertoli cells and in vitro co-culture of mammal cells with sertoli cells
US5624938A (en) * 1994-07-18 1997-04-29 The Trustees Of Columbia University In The City Of New York Use of chloroquine to treat multiple sclerosis
US6376528B1 (en) * 1996-02-13 2002-04-23 G. D. Searle & Co. Immunosuppressive effects of administration of a cyclooxygenase-2 inhibitor and a 5-lipoxygenase inhibitor
US20040259790A1 (en) * 2003-01-30 2004-12-23 Bali Pulendran Methods for identifying and administering agents that bias the immune response via dendritic cells
US20050004144A1 (en) * 2003-04-14 2005-01-06 Regents Of The University Of California Combined use of IMPDH inhibitors with toll-like receptor agonists

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ALIPRANTIS A.O. ET AL: "Cell Activation and Apoptosis by Bacterial Lipoproteins Through Toll-like Receptor-2", SCIENCE, vol. 285, 30 July 1999 (1999-07-30), pages 736 - 739, XP000985942 *

Also Published As

Publication number Publication date
WO2005079419A2 (en) 2005-09-01

Similar Documents

Publication Publication Date Title
WO2005079419A3 (en) Methods of treating immunopathological disorders
WO2006066008A3 (en) Device and methods for identifying and treating aspirin non-responsive patients
WO2006066088A3 (en) Methods for treating autoimmune disorders
WO2020112889A3 (en) Methods for treating dysregulated lipid metabolism
WO2008085229A3 (en) Cell-based therapies for treating liver disease
IL186386A0 (en) Active compression screw system and method for using the same
WO2006105527A3 (en) Amylin and amylin agonists for treating psychiatric diseases and disorders
WO2005117972A3 (en) Preventing autoimmune disease by using an anti-cd20 antibody
WO2008002933A3 (en) Combination of fcgammariib antibodies and cd20-specific antibodies and methods of use thereof
WO2007075702A3 (en) Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist
WO2009148954A3 (en) Tpo mimetic peptide for preventing hematological disorder associated with cancer treatment
WO2007122382A3 (en) Lycopene for the treatment of metabolic dysfunction
WO2015031598A3 (en) Therapeutic dnp derivatives and methods using same
WO2007095161A3 (en) Methods and compositions for treating disorders associated with increased bone turnover and osteopenia
WO2009121847A3 (en) Binding agents directed against il-4 receptor for the treatment of tumors, inflammatory and immunological disorders
WO2006009698A3 (en) Antagonizing an adenosine a2a receptor to amelioriate one or more components of addictive behavior
WO2005011605A3 (en) Combination therapies for multiple sclerosis
WO2005051293A3 (en) Methods and reagents for the treatment of inflammatory disorders
MX2010002559A (en) Compositions and methods for treating immunological and inflammatory diseases and disorders.
Liu et al. Some new additive Runge–Kutta methods and their applications
WO2016140910A3 (en) Compositions and methods of using anti-mullerian hormone for treatment of infertility
WO2006092741A3 (en) Treatment of inflammatory disorders with praziquantel
WO2006076525A3 (en) Combination cancer therapy with anti-psma antibodies
WO2009045900A3 (en) Methods for treating or preventing diseases associated with low bone mass
WO2009002790A3 (en) Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase